

November 3, 2022



# XORTX Announces Participation at Upcoming Investor Conferences

CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that Dr. Allen Davidoff, President and CEO, is scheduled to participate in the following upcoming investor conferences:

## **Sidotti & Company LLC - November Micro-Cap Virtual Conference**

Registration: [Sidoti & Co November 9-10 2022 Micro-Cap Virtual Investor Conference Registration](#)

## **A.G.P.'s Virtual Biotech Conference**

Registration: [Alliance Global Partners Nov 30th-Dec 1st 2022 Virtual Biotech Investor Conference Registration](#)

## **Singular Research's Best of the Uncovereds**

Registration: [Singular Research's Best of the Uncovereds Conference Dec. 8th 2022 San Francisco Registration](#)

## **About XORTX Therapeutics Inc.**

XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead program in XRx-008 for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX is available at [www.xortx.com](http://www.xortx.com).

For further information, please contact:

Allen Davidoff, CEO

[adavidoff@xortx.com](mailto:adavidoff@xortx.com) or +1 403 455 7727

Nick Rigopoulos, Director of Communications

[nick@alpineequityadv.com](mailto:nick@alpineequityadv.com) or +1 617 901 0785

Media Inquiries, David Melamed, Ph.D.

[david.melamed@russopartnersllc.com](mailto:david.melamed@russopartnersllc.com) or +1 212 845 4225

*The TSX Venture Exchange and Nasdaq have neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.*

### **Forward Looking Statements**

This press release may contain express or implied forward-looking statements pursuant to Canadian and U.S. Federal securities laws. These forward-looking statements and their implications are based on the current reasonable expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in such forward-looking statements. Except as otherwise required by law, XORTX undertakes no obligation to publicly release any revisions or updates to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained in the Company's most recently filed Annual Information Form and the Management Discussion and Analysis for its most recent financial reporting period filed on the Company's SEDAR profile ([www.sedar.com](http://www.sedar.com)) and under the heading "Risk Factors" in XORTX's Registration Statement on Form F-1 filed with the Securities and Exchange Commission ("SEC") available on the SEC's website, [www.sec.gov](http://www.sec.gov).



Source: XORTX Therapeutics Inc.